Correction: A previous version of this story incorrectly listed an associate not actually on the deal for Latham & Watkins. Alexander Berg did not work on the deal, instead it is Alexander White, out of the Menlo Park office.

SAN FRANCISCO — Latham & Watkins advised Menlo Park-based Avalanche Biotechnologies Inc. in filing its initial public offering. The clinical stage biotechnology firm listed 6 million shares of common stock at $17 a share on July 31, looking to raise $102 million.